PMC10352835_01
(A) The maximum intensity projection of the PET/CT scan shows increased 18F-FDG uptake in the right larynx (black arrow), bilateral supraclavicular area and right cervical area (white arrow), bilateral sacrum (white triangle), and left ilium (black triangle). (B, PET; C, CT; D, PET/CT fusion images) axial images of laryngeal mass. (E, PET; F, CT; G, PET/CT fusion images) sagittal images of the laryngeal mass. (H, PET; I, CT; J, PET/CT fusion images) coronal images of the laryngeal mass (SUVmax = 17.0; arrows). Besides, the axial CT (K,M) and fused PET/CT (L,N) images show that increased 18F-FDG uptake of bilateral sacrum (SUVmax = 8.0) and left iliac crest (SUVmax = 7.1) in the absence of obvious structural alterations. CT, computed tomography; 18F-FDG, fluoro-18-fluorodeoxyglucose; PET, positron emission tomography; SUVmax, maximum standardized uptake value.
fmed-10-1167350-g001.jpg
PMC10352835_01_fmed-10-1167350-g001.jpg
fig1
Moreover, the bilateral sacrum and left iliac bone also had markedly increased radiopharmaceutical uptake (Figure 1).
Tumor histopathology and immunohistochemical staining. (A) The tumor sections are stained with hematoxylin and eosin. The tumor cells are small and round, with relatively regular nuclei. (B) Immunohistochemistry is positive for CD99. (C) Immunohistochemical staining shows the positive expression of vimentin in tumor cells. (D) Immunohistochemistry reveals that Syn tests positive.
fmed-10-1167350-g002.jpg
PMC10352835_01_fmed-10-1167350-g002.jpg
fig2
Immunohistochemistry (IHC) results showed that the tumor cells positively expressed synaptophysin (Syn), vimentin, CD99, and P53 and negatively expressed S100, cytokeratin (CK), and neuron-specific enolase (NSE) (Figure 2).